Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study
Asher Chanan-Khan, Paula Cramer, Fatih Demirkan, Graeme Fraser, Rodrigo Santucci Silva, Sebastian Grosicki, Aleksander Pristupa, Ann Janssens, Jiri Mayer, Nancy L. Bartlett, Marie Sarah Dilhuydy, Halyna Pylypenko, Javier Loscertales, Abraham Avigdor, Simon Rule, Diego Villa, Olga Samoilova, Panagiots Panagiotidis, Andre Goy, Anthony MatoMiguel A. Pavlovsky, Claes Karlsson, Michelle Mahler, Mariya Salman, Steven Sun, Charles Phelps, Sriram Balasubramanian, Angela Howes, Michael Hallek
Dive into the research topics of 'Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study'. Together they form a unique fingerprint.